Edition:
United States

Veru Inc (VERU.OQ)

VERU.OQ on NASDAQ Stock Exchange Capital Market

1.75USD
23 Apr 2018
Change (% chg)

$-0.03 (-1.69%)
Prev Close
$1.78
Open
$1.77
Day's High
$1.77
Day's Low
$1.75
Volume
14,137
Avg. Vol
26,572
52-wk High
$2.99
52-wk Low
$0.90

Chart for

About

Veru Inc., formerly The Female Health Company, is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men's and women's health and oncology. The Company is engaged in the development, manufacture and marketing of consumer healthcare products. The Company has three divisions: Pharmaceut... (more)

Overall

Beta: 0.66
Market Cap(Mil.): $94.72
Shares Outstanding(Mil.): 53.51
Dividend: --
Yield (%): --

Financials

  VERU.OQ Industry Sector
P/E (TTM): -- 30.21 32.78
EPS (TTM): -0.27 -- --
ROI: -18.82 13.61 13.21
ROE: -28.74 15.28 15.01

BRIEF-U.S. FDA Grants Fee Waiver For Tamsulosin Drs New Drug Application

* FDA GRANTS FEE WAIVER FOR TAMSULOSIN DRS NEW DRUG APPLICATION

Mar 22 2018

BRIEF-Veru Says On March 5 Entered Into Credit Agreement For Synthetic Royalty Financing Transaction

* VERU SAYS ON MARCH 5, ENTERED INTO CREDIT AGREEMENT FOR SYNTHETIC ROYALTY FINANCING TRANSACTION - SEC FILING

Mar 06 2018

BRIEF-Veru Q1 Loss Per Share $0.08

* REMAIN ON TRACK TO FILE WITH FDA COMPANY'S FIRST NDA FOR TAMSULOSIN DRS IN 2018

Feb 14 2018

BRIEF-Veru to Present At 2018 Genitourinary Cancers Symposium

* VERU ANNOUNCES PRESENTATION OF DATA DEMONSTRATING EFFICACY OF VERU-111 IN A TAXANE RESISTANT HUMAN PROSTATE CANCER MODEL AT THE 2018 GENITOURINARY CANCERS SYMPOSIUM

Feb 06 2018

BRIEF-Veru reports Q4 Loss Per Share $0.10

* VERU REPORTS FISCAL 2017 FOURTH-QUARTER, FULL-YEAR FINANCIAL RESULTS

Jan 02 2018

BRIEF-Veru Inc Files For Non-Timely 10-K

* VERU - DUE TO TECHNICAL DIFFICULTIES AT THIRD PARTY FILING AGENT, CO'S 10-K WAS TRANSMITTED, RECEIVED FOR FILING ON EDGAR AT 5:33 PM ET ON DEC 29, 2017 Source text (http://bit.ly/2EzynHN) Further company coverage:

Jan 02 2018

BRIEF-Veru Acquires Novel Proprietary Formulation For Overactive Bladder

* VERU ACQUIRES NOVEL PROPRIETARY FORMULATION FOR OVERACTIVE BLADDER

Dec 11 2017

BRIEF-Veru announces Tamsulosin drs bioequivalence clinical trial results

* Veru announces Tamsulosin Drs bioequivalence clinical trial results

Nov 13 2017

BRIEF-Veru files for mixed shelf of up to $50 million

* Files for mixed shelf of up to $50 million - SEC filing‍​ Source text: (http://bit.ly/2lfqJfT) Further company coverage:

Oct 25 2017

Earnings vs. Estimates